11:07 AM EST, 11/19/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending lower late Wednesday morning, declining 0.32% to 1,578.76 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis ( CLLS ) and pharmaceutical company Novo Nordisk ( NVO ) , which advanced 11% and 2.1%, respectively. They were followed by lender Banco Santander (SAN) and biopharmaceutical company DBV Technologies ( DBVT ) , which increased 1.6% and 1.4%, respectively.

The decliners from continental Europe were led by telecommunications company Nokia ( NOK ) and biopharmaceutical company Genfit ( GNFT ) , which fell 7.5% and 5.3%, respectively. They were followed by petroleum refiner Equinor ( EQNR ) and biotech firm Evaxion ( EVAX ) , which were down 3.9% and 2.9%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group ( MREO ) and Amarin ( AMRN ) , which rose 3.3% and 3.1%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics ( BCYC ) and Akari Therapeutics ( AKTX ) , which were up 3% and 2.3%, respectively.

The decliners from the UK and Ireland were led by oil and gas companies Shell (SHEL) and BP (BP), which dropped 2.4% each. They were followed by lender Lloyds Banking Group ( LYG ) and pharmaceutical company Silence Therapeutics ( SLN ) , which lost 1.8% and 1.5%, respectively.